← Eichor
Study identifier: NCT06632327 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

Condition: Resectable Lung Non-Small Cell Carcinoma · Stage II Lung Cancer AJCC v8 · Stage IIIA Lung Cancer AJCC v8  ·  Sponsor: Alliance for Clinical Trials in Oncology

PhasePhase 3
Planned participants1100
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is i…

This description comes directly from the study's public registry record.

Talk to the study team

Kathryn Kelley, MPH  ·  (773) 702-9171  ·  kathryn.kelley@bsd.uchicago.edu

Always discuss trial participation with your own doctor first.

Locations (382)

University of Alabama at Birmingham Cancer CenterBirmingham, Alabama, United StatesActive Not Recruiting
Fairbanks Memorial HospitalFairbanks, Alaska, United StatesRecruiting
Cancer Center at Saint Joseph'sPhoenix, Arizona, United StatesRecruiting
Mayo Clinic Hospital in ArizonaPhoenix, Arizona, United StatesRecruiting
Mercy Hospital Fort SmithFort Smith, Arkansas, United StatesRecruiting
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - JonesboroJonesboro, Arkansas, United StatesRecruiting
CARTI Cancer CenterLittle Rock, Arkansas, United StatesRecruiting
Kaiser Permanente-Deer Valley Medical CenterAntioch, California, United StatesActive Not Recruiting
Mission Hope Medical Oncology - Arroyo GrandeArroyo Grande, California, United StatesRecruiting
Mercy Cancer Center - CarmichaelCarmichael, California, United StatesRecruiting
Mercy San Juan Medical CenterCarmichael, California, United StatesRecruiting
Enloe Medical CenterChico, California, United StatesRecruiting

+ 370 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06632327